TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00714285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' quadrivalent influenza vaccine
Description: Single intramuscular dose on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' quadrivalent influenza vaccine
Description: Single intramuscular dose on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' trivalent influenza vaccine
Description: Single intramuscular dose on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' trivalent influenza vaccine
Description: Single intramuscular dose on Day 0.
Study: NCT00131248

Intervention type: DRUG
Group type: OTHER
Intervention: Ranitidine

Intervention type: DRUG
Group type: OTHER
Intervention: Ranitidine

Intervention type: DRUG
Group type: OTHER
Intervention: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study: NCT02281916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P28GST
Description: 3 injections of 100 µg of P28GST within 3 months (one injection per month)
Study: NCT02030652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent nasal positive pressure positive ventilation.
Study: NCT02005809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: second look endoscopy
Description: Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
Study: NCT03551223

Intervention type: BIOLOGICAL
Intervention: Neuron specific enolase (NSE)
Description: 5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.

Intervention type: BIOLOGICAL
Intervention: Neuron specific enolase (NSE)
Description: 5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
Study: NCT02030652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nasal continuous positive airway pressure
Study: NCT00649207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Oral Capsules

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: 15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
Study: NCT02504151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04522232

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional Total laparoscopic hysterectomy
Description: the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
Description: the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy
Study: NCT01702649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX2003 (Biapenem)
Description: Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day.
Study: NCT01812252

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine (AZC)
Description: Given IV or SC

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Given IV or SC

Intervention type: OTHER
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01957007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered IV.
Study: NCT03077347

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study: NCT02989558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus ASA
Description: Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel plus ASA
Description: Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
Study: NCT04309240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10mg orally per day for 90days
Study: NCT02229500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5 g of propionate
Description: This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 g of propionate
Description: This delivers approximately 5g of propionate to the colon per 10g dose
Study: NCT03306732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (100ml)
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)
Study: NCT03243383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DiaTOHC Program
Description: 1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support
Study: NCT00630656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin alfa
Description: 15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study: NCT02167750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
Study: NCT04670614

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve Block with ropivicaine 0.5% Injectable Solution
Description: Peripheral nerve blocks using 0.5% ropivicaine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve Block with Placebo sham control of 0.9% Normal Saline
Description: Peripheral Nerve Block with placebo 0.9% normal saline
Study: NCT02963389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim
Study: NCT02410668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise recommendation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise recommendation
Study: NCT01796587

Intervention type: DEVICE
Intervention: LoFric Origo
Study: NCT03374189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ close
Description: EZ close used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carter Thomason
Description: Carter Thomason used.
Study: NCT01356407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PICOPREP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Study: NCT01957007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vantictumab
Description: Vantictumab will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vantictumab
Description: Vantictumab will be administered intravenously
Study: NCT01826279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500mg 3 times daily for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet 3 times daily for 1 month
Study: NCT04585464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: EDG-5506 is administered orally as a single dose or once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: EDG-5506 is administered orally as a single dose or once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: EDG-5506 is administered orally as a single dose or once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as a single dose or once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as a single dose or once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as a single dose or once daily
Study: NCT04351984

Intervention type: DEVICE
Intervention: MitraClip
Description: Transcatheter Mitral Valvuloplasty with MitraClip
Study: NCT01059669

Intervention type: OTHER
Intervention: diagnostic test

Intervention type: OTHER
Intervention: diagnostic test
Study: NCT02947035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroid lobectomy
Description: Thyroid lobectomy is removal of only part of the thyroid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with CCND
Description: Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
Study: NCT02690155

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians

Intervention type: DRUG
Intervention: VKA (Vitamin K antagonist)
Description: As prescribed by treating physicians
Study: NCT04502251

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: 4.5mg daily dose, orally, during 26 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: 4.5mg daily dose, orally, during 26 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham-tDCS stimulation consists of an active current during 30 seconds

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham-tDCS stimulation consists of an active current during 30 seconds
Study: NCT00579371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islets of Langerhans
Description: Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
Study: NCT01997736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Study: NCT01106170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provex CV
Description: dietary supplement, 2 capsules per day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provex CV
Description: dietary supplement, 2 capsules per day by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: corn starch, 2 capsules per day by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: corn starch, 2 capsules per day by mouth
Study: NCT04016480

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
Study: NCT02817321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection TPVB + continuous TPVB
Description: Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX50 Ultrasound Scanner
Description: The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK Contiplex S Catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose ropivacaine
Description: * 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuously infusion of ropivacaine
Description: * 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study: NCT00518154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine tablets
Description: Patients will take 30mg tid PO for 12 weeks
Study: NCT01468584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (generic name:Telaprevir)
Description: 750mg q8h for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: 1.5mcg/kg/week for 24 weeks
Study: NCT02816307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT02785250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat (INCB024360)
Description: PO BID
Study: NCT02601521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal tobacco coach
Description: The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: External tobacco coach
Description: Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
Study: NCT03168880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel only
Study: NCT03548935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
Study: NCT04536688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS4326
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS4326
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS4326
Description: Solution for subcutaneous injection